Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Incretin-based therapies

8 evidence topics · 7 sources

Tirzepatide: SYNERGY-NASH phase 2 trial in MASH with F2 or F3 fibrosis, 190 randomized participants with missing week 52 biopsies imputed

“We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote